Skip to content

Investigation of food-drug interaction mediated by CYP3A inhibition by Spirulina administration

Investigation of food-drug interaction mediated by CYP3A inhibition after short-term administration of Spirulina in Japanese healthy male subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031240397
Enrollment
6
Registered
2024-10-11
Start date
2024-10-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none Healthy volunteer

Interventions

Oral administration of Lina Green 21 Premium, a supplement containing midazolam and spirulina, to healthy adult males.

Sponsors

Takehiko Sambe
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Age: 18 years old or older and under 45 years old at the time of obtaining consent. 2) Gender: male 3) BMI: 18.5 kg/m2 or more but less than 30.0 kg/m2 4) Persons who have the ability to consent, abide by the rules of compliance during participation in the study, undergo the pre-test specified in this study protocol, and are able to report subjective symptoms, etc. (5) Persons who have been judged by the physician in charge of the research to be eligible to participate in this study based on the preliminary examination specified in the protocol for this study.

Exclusion criteria

Exclusion criteria: Persons who have any of the following will not be included in this study. (1) Persons with a history of drug abuse or dependence, alcohol abuse or dependence, or heart, liver, renal, pulmonary, ocular, or hematologic disease that may affect the safety or the evaluation of this study. (2) Patients who are taking drugs (including dietary supplements and dietary supplements) that may affect the evaluation and safety of this study. (3) Have a history of drug allergy (4) Persons who regularly use excessive amounts of alcohol (those who are unable to maintain abstinence from alcohol during the study period) (5) Those who have participated in other clinical trials within 3 months of the study. (6) Other subjects who are judged by the investigator to be ineligible for the study.

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters of serum midazolam (AUC, Cmax)

Secondary

MeasureTime frame
Pharmacokinetic parameters of serum midazolam (t1/2, tmax)

Contacts

Public ContactRyu Kakei

SHOWA Medical University

ryu-k@med.showa-u.ac.jp+81-3-3300-5247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026